ArticleNature communications2020
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.
0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 145 citations in OpenAlex.
- ATP-dependent chromatin remodelers in prostate cancer progression and therapeutic resistance.Endocrinology · 2026Review
- The roles of chromatin remodeling and 3D genome organization in cancers: from mechanistic insights to emerging treatment options.Molecular cancer · 2026Review
- A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.The Journal of experimental medicine · 2026Article
- Review
- 3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer.Endocrinology · 2026Review
- Game of clones: decipher lineage plasticity in hormone-driven cancers.Cellular and molecular life sciences : CMLS · 2026Review
- A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules.Cancer research · 2026Article
- SMARCA4 promotes lineage plasticity and enzalutamide resistance in prostate cancer by regulating PROX1 via H3K27 acetylation.Cell death discovery · 2026Article
- Implications for clinical prognosis and target discovery of the SWI/SNF complex in genitourinary tumors.Discover oncology · 2026Review
- mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion.bioRxiv : the preprint server for biology · 2026Article
- ERRγ impedes neuroendocrine prostate cancer development.Genes & development · 2026Article
- Genetic and epigenetic mechanisms underlying treatment-induced neuroendocrine prostate cancer.Journal of the National Cancer Center · 2026Review
- Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer.Journal of the National Cancer Center · 2026Review
- Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer.Journal of the National Cancer Center · 2026Review
- RUNX1T1 drives stem-like small-cell neuroendocrine prostate cancer identity.Frontiers in cell and developmental biology · 2026Article
- The Quartet of Core Oncogenic Drivers in Neuroendocrine Prostate Cancer: Multi-Omics Dataset Integration to Forge a Translational Link Between Biology and Precision Therapy.International journal of biological sciences · 2026Review
- PROCA11 early activation fuels prostate cancer neuroendocrine traits by regulating cell survival and migration.iScience · 2025Article
- Review
- LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer.Cancer research · 2025Article
- Circadian regulator REV-ERBα is a master regulator of tumor lineage plasticity and an effective therapeutic target.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 9 institutions in 7 countries.
Joanna CyrtaDepartment for BioMedical Research, University of Bern, 3008, Bern, Switzerland.
Anke AugspachDepartment for BioMedical Research, University of Bern, 3008, Bern, Switzerland.
Maria Rosaria De FilippoDepartment for BioMedical Research, Urology Research Laboratory, University of Bern, 3008, Bern, Switzerland.
Davide PrandiDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38122, Trento, Italy.
Phillip ThiengerDepartment for BioMedical Research, University of Bern, 3008, Bern, Switzerland.
Matteo BenelliDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38122, Trento, Italy.ORCID 0000-0003-1227-356X
Victoria CooleyDepartment of Healthcare Policy and Research, Division of Biostatistics and Epidemiology, Weill Cornell Medicine, New York, NY, 10021, USA.
Rohan BarejaThe Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, 10021, USA.
David WilkesThe Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, 10021, USA.ORCID 0000-0002-2422-1145
Sung-Suk ChaeDepartment of Laboratory Medicine and Pathology, Weill Cornell Medicine, New York, NY, 10021, USA.
Paola CavaliereMeyer Cancer Center, Weill Cornell Medicine, New York, NY, 10021, USA.
Noah DephoureMeyer Cancer Center, Weill Cornell Medicine, New York, NY, 10021, USA.
Anne-Christine UldryProteomics Mass Spectrometry Core Facility, University of Bern, 3010, Bern, Switzerland.
Sophie Braga LagacheProteomics Mass Spectrometry Core Facility, University of Bern, 3010, Bern, Switzerland.
Luca RomaInstitute of Pathology and Medical Genetics, University Hospital Basel, University of Basel, 4051, Basel, Switzerland.
Sandra CohenDepartment of Laboratory Medicine and Pathology, Weill Cornell Medicine, New York, NY, 10021, USA.
Muriel JaquetDepartment for BioMedical Research, University of Bern, 3008, Bern, Switzerland.
Laura P BrandtDepartment for BioMedical Research, University of Bern, 3008, Bern, Switzerland.
Mohammed AlshalalfaDepartment of Radiation Oncology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA.ORCID 0000-0001-8405-3035
Loredana PucaDepartment of Medicine, Division of Medical Oncology, Weill Cornell Medicine, New York, NY, 10021, USA.
Andrea SbonerThe Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, 10021, USA.
Felix FengProteomics Mass Spectrometry Core Facility, University of Bern, 3010, Bern, Switzerland.ORCID 0000-0002-0963-7687
Shangqian WangHuman Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA.
Himisha BeltranDepartment of Medicine, Division of Medical Oncology, Weill Cornell Medicine, New York, NY, 10021, USA.ORCID 0000-0003-3259-2226
Tamara LotanDepartment of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Martin SpahnLindenhofspital Bern, Prostate Center Bern, 3012, Bern, Switzerland.
Marianna Kruithof-de JulioDepartment for BioMedical Research, University of Bern, 3008, Bern, Switzerland.ORCID 0000-0002-6085-7706
Yu ChenDepartment of Medicine, Division of Medical Oncology, Weill Cornell Medicine, New York, NY, 10021, USA.ORCID 0000-0002-0171-3884
Karla V BallmanDepartment of Healthcare Policy and Research, Division of Biostatistics and Epidemiology, Weill Cornell Medicine, New York, NY, 10021, USA.
Francesca DemichelisThe Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, 10021, USA.ORCID 0000-0002-8266-8631
Salvatore PiscuoglioInstitute of Pathology and Medical Genetics, University Hospital Basel, University of Basel, 4051, Basel, Switzerland.
Mark A RubinDepartment for BioMedical Research, University of Bern, 3008, Bern, Switzerland. mark.rubin@dbmr.unibe.ch.ORCID 0000-0002-8321-9950
Cornell University · USUniversity of Bern · CHUniversity of Trento · ITUniversity of Basel · CHEssen University Hospital · DEJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · USPrince Sattam Bin Abdulaziz University · SAUCSF Helen Diller Family Comprehensive Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MWeill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LODA, MASSIMO · 2017 to 2021
$10.9MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8MPatient-Derived Models of Prostate Cancer for Personalized MedicineU01CA224044 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, YU, FUTREAL, PHILLIP ANDREW · 2019 to 2023
$5.1MMolecular mechanisms underlying lineage plasticity in prostate cancerR37CA241486 · NCI · DANA-FARBER CANCER INST · PI Himisha Beltran · 2020 to 2026
$4.1MTowards Understanding Prostate Cancer HeterogeneityR01CA125612 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI RUBIN, MARK A. · 2007 to 2017
$3.4MCollaborative genomic alterations and transcriptional control in prostate cancerR01CA233650 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BARBIERI, CHRISTOPHER E · 2019 to 2023
$2.8MUnderstanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistanceR01CA208100 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2017 to 2021
$2.5MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA211024NCI NIH HHS R01 CA125612NCI NIH HHS R01 CA208100NCI NIH HHS R01 CA233650NCI NIH HHS R37 CA241486NCI NIH HHS U01 CA224044NCI NIH HHS U54 CA224079
Abstract
Advanced prostate cancer initially responds to hormonal treatment, but ultimately becomes resistant and requires more potent therapies. One mechanism of resistance observed in around 10-20% of these patients is lineage plasticity, which manifests in a partial or complete small cell or neuroendocrine prostate cancer (NEPC) phenotype. Here, we investigate the role of the mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complex in NEPC. Using large patient datasets, patient-derived organoids and cancer cell lines, we identify mSWI/SNF subunits that are deregulated in NEPC and demonstrate that SMARCA4 (BRG1) overexpression is associated with aggressive disease. We also show that SWI/SNF complexes interact with different lineage-specific factors in NEPC compared to prostate adenocarcinoma. These data point to a role for mSWI/SNF complexes in therapy-related lineage plasticity, which may also be relevant for other solid tumors.
Indexed as
Cell LineageCell PlasticityAdenocarcinomaCell Line, TumorChromosomal Proteins, Non-HistoneCohort StudiesDNA HelicasesGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMaleModels, BiologicalNeoplasm InvasivenessNeoplasm ProteinsNeuroendocrine TumorsNuclear ProteinsChromosomal Proteins, Non-HistoneDNA HelicasesNeoplasm ProteinsNuclear ProteinsProtein SubunitsSMARCA4 protein, humanSWI-SNF-B chromatin-remodeling complexTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.